Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial
Mikhail N. Kosiborod, Russell Esterline, Remo H.M. Furtado, Jan Oscarsson, Samvel B. Gasparyan, Gary G. Koch, Felipe Martinez, Omar Mukhtar, Subodh Verma, Vijay Chopra, Joan Buenconsejo, Anna Maria Langkilde, Philip Ambery, Fengming Tang, Kensey Gosch, Sheryl L. Windsor, Emily E. Akin, Ronaldo V.P. Soares, Diogo D.F. Moia, Matthew AboudaraConrado Roberto Hoffmann Filho, Audes D.M. Feitosa, Alberto Fonseca, Vishnu Garla, Robert A. Gordon, Ali Javaheri, Cristiano P. Jaeger, Paulo E. Leaes, Michael Nassif, Michael Pursley, Fabio Serra Silveira, Weimar Kunz Sebba Barroso, José Roberto Lazcano Soto, Lilia Nigro Maia, Otavio Berwanger
Dive into the research topics of 'Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial'. Together they form a unique fingerprint.